Key result
Laropiprant, either alone or combined with extended-release niacin, did not increase urinary 11-dehydrothromboxane B2 levels compared to placebo or niacin alone after 7 days of administration.
Why the study?
Does laropiprant, with or without extended-release niacin, increase urinary 11-dehydrothromboxane B2 levels (a marker of platelet activation) in healthy, hypercholesterolemic, and diabetic subjects?
RCT
Does laropiprant, with or without extended-release niacin, increase urinary 11-dehydrothromboxane B2 levels (a marker of platelet activation) in healthy, hypercholesterolemic, and diabetic subjects?
Laropiprant, used to reduce niacin-induced flushing, does not increase in vivo platelet activation, alleviating concerns about potential prothrombotic effects from DP1 receptor antagonism.
Alleviates prothrombotic concerns with DP1 antagonism for niacin flushing; confirms no short-term platelet activation in RCT.
Laropiprant, an antagonist of the PGD(2) receptor, DP1, is effective in reducing the flushing symptoms associated with extended-release (ER) niacin and thereby improves the tolerability of niacin therapy for dyslipidemia. Because PGD(2) has been reported to inhibit platelet aggregation in vitro, it has been speculated that antagonism of DP1 may enhance platelet reactivity. Three clinical studies evaluated the potential effect of laropiprant, with or without coadministration of ER niacin, on in vivo platelet function in healthy subjects and hypercholesterolemic or diabetic subjects by measuring urinary levels of 11-dehydrothromboxane B(2) (11-dTxB(2)), a marker of in vivo platelet activation. Following 7 days of multiple-dose administration, coadministration of laropiprant with ER niacin did not increase urinary 11-dTxB(2) levels compared to ER niacin alone in healthy, hypercholesterolemic, or diabetic subjects. In hypercholesterolemic and diabetic subjects, laropiprant did not increase urinary 11-dTxB(2) levels compared to placebo. These results demonstrate that laropiprant does not enhance in vivo platelet reactivity, either alone or in combination with niacin.
No takes yet. Share an insight, caveat, or question.
Lauring et al. (2009) conducted an RCT in Hypercholesterolemia and diabetes. Laropiprant with or without extended-release (ER) niacin vs. ER niacin alone or placebo was evaluated on Urinary levels of 11-dehydrothromboxane B(2) (11-dTxB(2)). Laropiprant, either alone or combined with extended-release niacin, did not increase urinary 11-dehydrothromboxane B2 levels compared to placebo or niacin alone after 7 days of administration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: